Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/bc/9a/25/bc9a2543-9afb-db02-2542-76a53abb51d4/mza_11785001901625621064.jpg/600x600bb.jpg
PeerVoice Heart & Lung Video
PeerVoice
79 episodes
3 days ago
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Show more...
Science
Education,
How To,
Health & Fitness,
Medicine
RSS
All content for PeerVoice Heart & Lung Video is the property of PeerVoice and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Show more...
Science
Education,
How To,
Health & Fitness,
Medicine
https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/bc/9a/25/bc9a2543-9afb-db02-2542-76a53abb51d4/mza_11785001901625621064.jpg/600x600bb.jpg
Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?
PeerVoice Heart & Lung Video
35 minutes 55 seconds
2 months ago
Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?
Visit https://www.peervoice.com/TQR860 to view the entire programme with slides. After completing “Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?”, participants will be able to: Recognise the rationale behind TROP2 as a therapeutic target in NSCLC; Recall the results of clinical trials assessing the safety and efficacy of TROP2-directed therapy across different types of NSCLC, including non-oncogene-addicted, EGFR-mutant and ALK-rearranged NSCLC; and Assess the clinical relevance of subgroup analyses evaluating the effect of TROP2-directed therapy in specific types of NSCLC (eg, EGFR-mutant NSCLC that has progressed after initial TKI therapy).
PeerVoice Heart & Lung Video
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.